When was Clementia founded?

Clementia was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is Clementia located?

Clementia is headquartered in Dorval, Canada.

How many employees does Clementia have?

As of Jul 31, 2026, the latest employee count at Clementia is 9.

Is Clementia a funded company?

Clementia is a funded company, having raised a total of $92.5M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2012.

When was the latest funding round of Clementia?

Clementia's latest funding was a $***** Series B round on Jul 06, 2015, with participation from 0 investor. Its primary sector is Rare Diseases. In Canada, the Rare Diseases sector has seen $59.7M in funding in 2026 to date.

Where does Clementia rank among its competitors?

Clementia ranks 97th amongst 280 active competitors, of which 77 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Clementia?

Clementia's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Clementia - 2026 Company Profile, Team, Funding & Competitors

Q: Is Clementia an acquired company?

Clementia got acquired by Ipsen on Feb 25, 2019.

Clementia is an acquired company based in Dorval (Canada), founded in 2012. It operates as a Small Molecule to treat rare bone diseases such as Fibrodysplasia Ossificans Progressiva (FOP).. Clementia has raised $92.5M in funding. The company has 280 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Clementia is developing treatments for people living with rare diseases by exploiting the science of novel retinoic acid receptor gamma agonists to address bone diseases, including Fibrodysplasia Ossificans Progressiva (FOP). Its lead product, Palovarotene is an investigational retinoic acid receptor gamma (RARγ) agonist that holds the potential to prevent the abnormal growth of bone in people with FOP. In 2014, palovarotene received Orphan Drug Designation from the FDA and Orphan Medicinal Product Designation from the European Medicines Agency (EMA).

Website: clementiapharma.com
Social

Key Metrics

Founded Year

2012

Location

Dorval, Canada

Stage

Acquired

Total Funding

$92.5M in 5 rounds

Latest Funding Round

Series B, Jul 06, 2015, $*****

Investors

RA Capital Management & 8 more

Ranked

97^th among 280 active competitors

Employee Count

9 as on Jul 31, 2026

Similar Companies

BridgeBio & 314 more

Exit Details

Acquired by Ipsen (Feb 25, 2019)

View Clementia's full profile

Clementia got acquired by Ipsen on Feb 25, 2019 at an acquisition amount of $*****.

Click here to take a look at Clementia's acquisition in detail

Clementia has raised a total funding of $92.5M over 5 rounds. Its first funding round was on 2012. Clementia has 9 institutional investors.

Here is the list of recent funding rounds of Clementia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 06, 2015	9937224	Series B	4915989	1138744	7307907	5514270
Jun 23, 2015	2708511	Conventional Debt	5407625	6508113	1232858	New Enterprise Associates & 7 more
Jan 05, 2015	7075906	Series A	7052079	4878188	8056412	Orbimed & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Clementia's funding rounds and investors

Clementia's employee count trend

Clementia has 9 employees as of Jul 26. Here is Clementia's employee count trend over the years:

Uncover Clementia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Clementia include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Clementia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
97th	Clementia 2012, Dorval (Canada), Acquired	Small Molecule to treat rare bone diseases such as Fibrodysplasia Ossificans Progressiva (FOP).	$92.5M	RA Capital Management, Janus Henderson Investors ... & 7 others	46/100